GSK grabs $1.25B cash and a cut of Gilead­'s megablock­buster Bik­tarvy sales as HIV ri­vals set­tle patent suit

Three years af­ter Vi­iV Health­care, the HIV spe­cial­ist ma­jor­i­ty owned by Glax­o­SmithK­line, first sued Gilead over al­leged patent in­fringe­ment on one of its top drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER